Table 3.
Total and incremental costs and outcomes associated with aQIV and HD-QIV when used to vaccine people aged 65+ in Spain.
| Category | Clinical Events | Costs (EUR Millions) | ||||
|---|---|---|---|---|---|---|
| Vaccine | HD-QIV | aQIV | Difference | HD-QIV | aQIV | Difference |
| Primary care visits | 54,946 | 54,186 | −760 | 3.42 | 3.37 | −0.05 |
| Emergency department visits | 12,332 | 12,161 | −171 | 2.26 | 2.23 | −0.03 |
| Hospitalization | 47,371 | 46,930 | −442 | 212.7 | 210.7 | −1.98 |
| Deaths | 2842 | 2816 | −26 | 0.0 | 0.0 | 0.0 |
| Vaccine cost * | 261.1 | 199.6 | −61.5 | |||
| Productivity loss | 60.7 | 60.1 | −0.6 | |||
| QALY loss | 21,040 | 20,833 | −206 | |||
| LYs lost | 27,940 | 27,679 | −260 | |||
| Total costs (public payer) | 479.5 | 415.9 | −63.6 | |||
| Total costs (societal) | 540.2 | 476.0 | −64.2 | |||
* Excludes administration costs which are equal across both vaccines. Abbreviations: aQIV = advanced QIV; HD-QIV = high-dose QIV; LY = life year; QALY = quality-adjusted life year.